Detection of CTL activity in PBMCS taken from HIV-ENV immunized individuals after in vitro viral infection

Biomed Pharmacother. 1994;48(1):7-10. doi: 10.1016/0753-3322(94)90184-8.

Abstract

The cellular immune response to the AIDS virus in healthy individuals immunized with HIV-1 antigens has not yet been entirely understood. Unlike HIV-1 infected patients where direct measurements of anti HIV-1 CTL activities can be readily performed with fresh peripheral blood mononuclear cells, uninfected volunteers immunized against HIV-1 antigens have fewer circulating CTL necessitating an in vitro activation in order to amplify the cytotoxic signal and make it measurable. This study presents experiments where specific CTLs are successfully obtained simply by in vitro infection of PBMCs from HIV-1 Envelope immunized individuals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / blood
  • Acquired Immunodeficiency Syndrome / immunology*
  • Acquired Immunodeficiency Syndrome / prevention & control
  • Gene Products, env / therapeutic use
  • HIV Antigens / immunology
  • HIV Envelope Protein gp160
  • HIV-1* / immunology
  • Healthy Worker Effect
  • Humans
  • Immunization
  • In Vitro Techniques
  • Protein Precursors / therapeutic use
  • T-Lymphocytes, Cytotoxic / immunology*

Substances

  • Gene Products, env
  • HIV Antigens
  • HIV Envelope Protein gp160
  • Protein Precursors